Evidence map›Paper›PMID 28493909›Full record

ArticlePloS one2017

HNF1α defect influences post-prandial lipid regulation.

Matthieu St-Jean, François Boudreau, André C Carpentier, Marie-France Hivert

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. HNF1A Mutations and Beta Cell Dysfunction in Diabetes.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Article
  6. Using Clinical Indices to Distinguish MODY2 (GCK Mutation) and MODY3 (HNF1A Mutation) from Type 1 Diabetes in a Young Chinese Population.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
    Article
  7. HNF1Journal of diabetes research · 2019
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Matthieu St-JeanDepartment of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada.
François BoudreauDepartment of Anatomy and Cellular Biology, University of Sherbrooke, Sherbrooke, Quebec, Canada.
André C CarpentierDepartment of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada.
Marie-France HivertDepartment of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada.ORCID http://orcid.org/0000-0001-7752-2585
Université de Sherbrooke · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHepatocyte nuclear factor 1 alpha (HNF1α) defects cause Mature Onset Diabetes of the Young type 3 (MODY3), characterized by defects in beta-cell insulin secretion. However, HNF1α is involved in many other metabolic pathways with relevance for monogenic or polygenic type 2 diabetes. We aimed to investigate gut hormones, lipids, and insulin regulation in response to a meal test in HNF1α defect carriers (MODY3) compared to non-diabetic subjects (controls) and type 2 diabetes (T2D).

methodsWe administered a standardized liquid meal to each participant. Over 6 hours, we measured post-meal responses of insulin regulation (blood glucose, c-peptide, insulin), gut hormones (ghrelin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1) and lipids (non-esterified fatty acids [NEFA] and triglycerides).

resultsWe found that MODY3 participants had lower insulin secretion indices than controls and T2D participants, showing the expected β-cell defect. MODY3 had similar glycated hemoglobin levels (HbA1c median [IQR]: 6.5 [5.6-7.6]%) compared to T2D (median: 6.6 [6.2-6.9]%; P<0.05). MODY3 had greater insulin sensitivity (Matsuda index: 71.9 [29.6; 125.5]) than T2D (3.2 [4.0; 6.0]; P<0.05). MODY3 experienced a larger decrease in the ratio of NEFA to insulin (NEFA 30-0 / insulin 30-0: -39 [-78; -30] x104) in the early post-prandial period (0-30 minutes) compared to controls and to T2D (-2.0 [-0.6; -6.4] x104; P<0.05). MODY3 had lower fasting (0.66 [0.46; 1.2] mM) and post-meal triglycerides levels compared to T2D (fasting: 2.3 [1.7; 2.7] mM; P<0.05). We did not detect significant post-meal differences in ghrelin and incretins between MODY3 and other groups.

conclusionIn response to a standard meal test, MODY3 showed greater early post-prandial NEFA diminution in response to relatively low early insulin secretion, and they maintained very low post-prandial triglycerides levels.

Indexed as

AdolescentAdultAgedBlood GlucoseChildC-PeptideDiabetes Mellitus, Type 2Fatty Acids, NonesterifiedFemaleGastric Inhibitory PolypeptideGhrelinGlucagon-Like Peptide 1Hepatocyte Nuclear Factor 1-alphaHumansInsulinMaleBlood GlucoseC-PeptideFatty Acids, NonesterifiedGastric Inhibitory PolypeptideGhrelinGlucagon-Like Peptide 1Hepatocyte Nuclear Factor 1-alphaInsulinTriglycerides

Identifiers

PMID28493909
PMCPMC5426708
OpenAlexW2612185793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.